[go: up one dir, main page]

AR055133A1 - Inhibidores de la p38- map - quinasa para el uso de los mismos - Google Patents

Inhibidores de la p38- map - quinasa para el uso de los mismos

Info

Publication number
AR055133A1
AR055133A1 ARP060103656A ARP060103656A AR055133A1 AR 055133 A1 AR055133 A1 AR 055133A1 AR P060103656 A ARP060103656 A AR P060103656A AR P060103656 A ARP060103656 A AR P060103656A AR 055133 A1 AR055133 A1 AR 055133A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocyclyl
heteroalkyl
heteroaryl
aryl
Prior art date
Application number
ARP060103656A
Other languages
English (en)
Inventor
Nolan James Dewdney
Tobias Gabriel
Kristen Lynn Mccaleb
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR055133A1 publication Critical patent/AR055133A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)

Abstract

Se describen también métodos para la obtencion de los compuestos de interés y métodos para el uso de los compuestos en el tratamiento de las enfermedades mediadas por la p38-MAP-quinasa. Reivindicacion 1: Un compuesto de la formula (1a) (1b), (1c), (1d), (1e), (1f), (1g) o (1h) o una sal farmacéuticamente aceptable del mismo, en las que: R1 esa arilo, heteroarilo, aralquilo o cicloalquilo; R2 es arilo, heteroarilo, cicloalquilo, alquilo ramificado, heterociclilo, hidroxialquilo, cicloalquenilo o hidroxicicloalquilo; R3 es H o alquilo; R4 es H, alquilo, hidroxi, amino, heteroalquilo, heterociclilo, heterociclilalquilo, hidroxicicloalquilo, cicloalquilalquilo, alquilsulfonilo, alquilsulfonamido, arilo, heteroarilo, aralquilo, heteroaralquilo, -(CHRa)r-C(=O)-Rb, -(CHRa) r-O-C(=O)-Rb, -(CHRa)r-NH-C(=O)-Rb o -SO2-Rb, en los que Ra es H, alquilo o heteroalquilo; Rb es alquilo, hidroxi, amino, heteroalquilo, arilo, aralquilo, heteroarilo, o heterociclilo; r es un numero de 0 a 4; R5 es H, -C(=O)-Rc, -(O=)P(ORd)2, -S(=O)2ORd o un mono-, di- o tri-péptido; R6 es -C(=O)-Rc o -(O=)P(ORd)2-, -S(=O)2ORd o un mono-, di- o tri-péptido; en los que Rc es alquilo, alcoxi, amino, cicloalquilo, cicloalquilalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquiloxi, cicloalquilalquiloxi, ariloxi, arilalquiloxi, heteroariloxi, heteroarilalquiloxi, heterociclilo, heterocicliloxi, -(CH2)p-C(=O)-Re, -(CH=CH)-C(=O)-Re, o -CH(NH2)-Rf; en los que Re es H, hidroxi, alcoxi o amino; p es 2 o 3; Rf es H, alquilo, hidroxialquilo, aminoalquilo, fenilo opcionalmente sustituido, bencilo, guanidinilalquilo, carboxialquilo, amidoalquilo, tioalquilo o imidazolalquilo; Rd es H, alquilo, un ion de metal alcalino o un ion de metal alcalinotérreo; X e Y son N, o uno de X e Y es N y el otro es CRg; en el que Rg es H, alquilo, hidroxi, alcoxi, amino, haloalquilo, ciano, halogeno, heteroalquilo, C(=O)-Rh o -SO2-Rh, en los que Rh es H o alquilo; D es -(CR7R8)n-; en el que n es un numero de 1 a 3; R7 y R8 con independencia entre sí son H o alquilo; W es un enlace, O, S(O)q, CH2 o NRi; E es O, S(O)q, CH2 o NRi; en los que q es un numero de 0 a 2; Ri es H, alquilo, heteroalquilo, heterociclilo, hidroxicicloalquilo, -C(=O)- Rj o -SO2-Rj, en los que Rj es alquilo, arilo, aralquilo, heteroarilo, heteroalquilo o heterociclilo; o R4 y Ri junto con los átomos a los que están unidos pueden formar un anillo heterocíclico; A es O, CH2, S(O)s, C(=O), NRk, o CH(ORk), en los que s es un numero de 0 a 2; Rk es H o alquilo; k es el numero 0 o 1; B es O, S(O)j, -(CHRm)t, -NRmSO2-, NRm, NRmC(=O) o C(=O), en los que j es el numero 0, 1 o 2; t es un numero de 1 a 3, y Rm es H o alquilo.
ARP060103656A 2005-08-25 2006-08-23 Inhibidores de la p38- map - quinasa para el uso de los mismos AR055133A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71200705P 2005-08-25 2005-08-25

Publications (1)

Publication Number Publication Date
AR055133A1 true AR055133A1 (es) 2007-08-08

Family

ID=37441925

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103656A AR055133A1 (es) 2005-08-25 2006-08-23 Inhibidores de la p38- map - quinasa para el uso de los mismos

Country Status (13)

Country Link
US (1) US7608603B2 (es)
EP (1) EP1919914A2 (es)
JP (1) JP2009506009A (es)
KR (1) KR20080039438A (es)
CN (1) CN101248077B (es)
AR (1) AR055133A1 (es)
AU (1) AU2006283945A1 (es)
BR (1) BRPI0615272A2 (es)
CA (1) CA2620106A1 (es)
IL (1) IL189382A0 (es)
MX (1) MX2008002590A (es)
TW (1) TW200740816A (es)
WO (1) WO2007023115A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
PE20170003A1 (es) 2009-08-17 2017-03-15 Intellikine Llc Compuestos heterociclicos y usos de los mismos
EP2678018A4 (en) 2011-02-23 2015-09-30 Intellikine Llc COMBINATION OF CHINESE HEMMER AND USES THEREOF
CA2907726A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
WO2016066673A1 (en) * 2014-10-30 2016-05-06 Sandoz Ag Synthesis of substituted 1h-pyrazolo[3,4-d]pyrimidines
EP3691620B1 (en) 2017-10-05 2022-07-27 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3102279A1 (en) 2018-06-01 2019-12-05 Cornell University Combination therapy for pi3k-associated disease or disorder
JP7431435B2 (ja) * 2019-11-14 2024-02-15 国立大学法人大阪大学 新規リゾホスファチジン酸誘導体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383790B1 (en) * 1999-01-11 2002-05-07 Princeton University High affinity protein kinase inhibitors
KR200294211Y1 (ko) 2002-07-26 2002-11-07 김관호 사각지대가 없는 자동차용 사이드 미러
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2005085249A1 (en) * 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
CA2619365A1 (en) * 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators

Also Published As

Publication number Publication date
KR20080039438A (ko) 2008-05-07
WO2007023115A3 (en) 2007-04-12
US20070049597A1 (en) 2007-03-01
BRPI0615272A2 (pt) 2009-08-04
US7608603B2 (en) 2009-10-27
TW200740816A (en) 2007-11-01
MX2008002590A (es) 2008-03-18
CN101248077A (zh) 2008-08-20
CN101248077B (zh) 2011-07-20
WO2007023115A2 (en) 2007-03-01
JP2009506009A (ja) 2009-02-12
IL189382A0 (en) 2008-06-05
AU2006283945A1 (en) 2007-03-01
EP1919914A2 (en) 2008-05-14
CA2620106A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
AR055133A1 (es) Inhibidores de la p38- map - quinasa para el uso de los mismos
JP2011251990A5 (es)
AR066348A1 (es) Inhibidores de las iap
TW200745029A (en) Sulfonamide derivatives exhibiting PGD2 receptor antagonism
CY1114318T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
RU2008134534A (ru) 3,5-ди(арилили гетероарил)изоксазолы и 1,2,4-оксадиазолы в качестве агонистов рецентора s1p1, иммунодепрессантных и противовоспалительных агентов
AR055619A1 (es) Diaminopirimidinas como moduladores p2x2/3
AR074459A1 (es) Pirrolopirazinil-ureas utiles para el tratamiento de enfermedades autoinmunes e inflamatorias.
AR060545A1 (es) Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas
ECSP066950A (es) Combinaciones de glicopirrolato y agonistas del adrenoceptor-beta2
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
RU2007104028A (ru) Ингибиторы iap
AR065499A1 (es) Inhibidores de serino proteasas.composiciones farmaceuticas
RU2016118768A (ru) Композиции, пригодные для лечения расстройств, связанных с kit
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
AR077143A1 (es) Compuestos insecticidas
EA200702497A1 (ru) Замещенные арилпиразолы для применения против паразитов
PE20060837A1 (es) COMPUESTOS DE 3H-OXAZOLO Y 3H-TIAZOLO[4,5-d]PIRIMIDIN-2-ONA 3,5-DISUSTITUIDA Y 3,5,7-TRISUSTITUIDA Y PROFARMACOS DE LOS MISMOS
TW200643015A (en) 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
AR053774A1 (es) Derivados de sulfonilbencimidazol. composiciones farmaceuticas.
AR057981A1 (es) Compuesto de pirroloquinolin -4- ona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios pra su preparacion
AR037938A1 (es) Derivados de avermectina b1 que tienen un substituyente de aminosulfoniloxilo en la posicion 4''
EP1176958A4 (en) NEW CATHECHOLE AS AN ANTIMICROBIAL AGENT
AR040126A1 (es) Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
RU2010115337A (ru) Трициклические гетероциклические производные

Legal Events

Date Code Title Description
FA Abandonment or withdrawal